Try our Advanced Search for more refined results
Life Sciences
- 
									September 08, 2025
									Oura Domestic Labor Investment Won Import Ban, ITC SaysThe U.S. International Trade Commission has found that Ouraring Inc.'s commitments in the U.S. to producing its smart ring warranted the agency's decision to block Ultrahuman and RingConn from importing products it held infringed a wearable computing device patent. 
- 
									September 08, 2025
									FisherBroyles Can't Nix Stem Cell Patent Malpractice ClaimA California judge on Monday denied FisherBroyles LLP's motion to toss a claim in a $10 million malpractice suit brought against it by a stem cell treatment center, ruling the firm missed a deadline to file the motion. 
- 
									September 08, 2025
									Whisper Not Enough To Sustain Worker's Harassment SuitA Pennsylvania federal judge tossed a Merck Sharp & Dohme worker's suit Monday claiming his boss sexually harassed him by whispering in his ear at a staff meeting, ruling the singular incident did not create a hostile work environment at the pharmaceutical company. 
- 
									September 08, 2025
									Trump Returns To High Court In Foreign Aid Freeze DisputePresident Donald Trump asked the U.S. Supreme Court on Monday to pause a lower court's order requiring the administration to release roughly $4 billion in frozen foreign aid, claiming the ruling interferes with his attempt to lawfully rescind the funding. 
- 
									September 08, 2025
									FibroGen To Pay SEC $1.25M Over Drug MistatementsBiopharmaceutical company FibroGen Inc. has agreed to pay a $1.25 million penalty to the U.S. Securities and Exchange Commission to resolve claims that its former chief medical officer fudged results for its primary drug, Roxadustat, which treats anemia in kidney disease patients. 
- 
									September 08, 2025
									Catching Up With Delaware's Chancery CourtLast week at the Delaware Court of Chancery, a bankruptcy administrator for a generic drugmaker formerly known as Teligent was told he can proceed with duty of oversight claims against most former officers and directors of the company, who the administrator said was complicit in the company's collapse. In an opinion, the Court of Chancery cites its 1996 decision In re Caremark International Inc. Derivative Litigation, which refined director duties of care and oversight. 
- 
									September 08, 2025
									23andMe's Ch. 11 Sale Flouted State Privacy Law, Calif. SaysThe state of California has asked a Missouri federal judge to undo the $305 million bankruptcy sale of consumer DNA testing group 23andMe, arguing it sidestepped state consumer data protections. 
- 
									September 05, 2025
									DC Circ. Won't Halt Order Releasing Billions In Foreign AidBoth a divided D.C. Circuit panel and a district court judge Friday refused to hit pause on the judge's recent order requiring the Trump administration to release billions of dollars in frozen foreign aid. 
- 
									September 05, 2025
									Stewart Tackles Markets, Injunctions In Newest PTAB ReviewsActing U.S. Patent and Trademark Office Director Coke Morgan Stewart released 14 institution decisions in the last week, providing more insight on the scope of settled expectations and the impact of a district court preliminary injunction. 
- 
									September 05, 2025
									Federal Agencies Push To Toss Masimo's Apple Watch SuitU.S. Customs and Border Protection and the U.S. International Trade Commission have again urged a federal judge to throw out Masimo's suit seeking to block a decision allowing imports of redesigned Apple Watches, saying Congress barred court review of such findings. 
- 
									September 05, 2025
									2nd Circ. Backs Ex-Pfizer Worker's Insider Trading ConvictionThe Second Circuit on Friday affirmed a former Pfizer Inc. statistician's insider trading conviction for making $272,000 in options trades from nonpublic news about the success of trials for the COVID-19 therapy drug Paxlovid, rejecting his arguments that prosecutors improperly shifted their legal theory at trial and pursued the case in the wrong venue. 
- 
									September 05, 2025
									DOJ Pushes To DQ Attorney Over Conflict In Fraud CaseFederal prosecutors in Georgia are seeking to disqualify an attorney from representing a defendant accused of making false statements in relation to a criminal fraud investigation of Hi-Tech Pharmaceuticals Inc., arguing the lawyer was previously disqualified from representing the company's CEO for a conflict and that "the same is true now." 
- 
									September 05, 2025
									Merck Shakes Off Some Claims From Cholesterol Drugs SuitA New Jersey federal judge has partly granted a request from Merck & Co. to dismiss claims brought by Humana over an alleged anticompetitive scheme to control distribution of cholesterol drugs Zetia and Vytorin, tossing several proposed theories of monopolization but allowing unjust enrichment claims and state law antitrust claims to survive. 
- 
									September 05, 2025
									Vein Tech Maker Wants Suit Over DOJ Kickback Probe TossedVein disease device maker Inari Medical Inc. and its former top brass have asked a New York federal judge to toss a proposed investor class action over claims the company's share price fell after it disclosed an investigation into its compliance with federal anti-kickback laws, arguing the suit fails to allege any specific kickbacks or false statements. 
- 
									September 05, 2025
									FDA Explains Rejection Of MDMA Therapy For Treating PTSDThe U.S. Food and Drug Administration rejected a historic new drug application to treat post-traumatic stress disorder with the psychedelic MDMA due to concerns with the drug's safety and effectiveness and with the design of the clinical trials behind the bid, according to an agency letter made public Thursday. 
- 
									September 05, 2025
									Casper Can't Escape Innovator-Liability Drug Label SuitA California federal judge won't let Casper Pharma LLC escape an innovator-liability suit alleging that its failure to provide adequate warnings on its gout treatment led to the death of a man who used its generic version. 
- 
									September 05, 2025
									Conn. Biotech Hits Ch. 11 With $2.7M Debt After Patent SuitA Connecticut biotech company has filed a voluntary Chapter 11 petition claiming at least $2.7 million in liabilities, mostly debts to Quinn Emanuel Urquhart & Sullivan LLP and Verrill Dana LLP, after both law firms represented it in a since-settled Massachusetts stem cell patent lawsuit. 
- 
									September 05, 2025
									Motley Rice Fights OptumRx DQ Bid In Utah Opioid SuitPharmacy benefit manager OptumRx cannot disqualify Motley Rice LLC from representing Utah in a lawsuit over the opioid crisis, since any information the firm obtained during its involvement in earlier government investigations is available to all other parties in the multidistrict litigation and so isn't confidential, the state has told a federal court. 
- 
									September 04, 2025
									Feds Seek Stay On Court Order Releasing Foreign Aid BillionsThe Trump administration urged the D.C. Circuit on Thursday to stay a federal judge's order that it release billions in frozen foreign aid pending its appeal, saying the disbursement will likely be "impossible" to recover according to the international aid organization plaintiffs' "own description of their financial condition." 
- 
									September 04, 2025
									Split 3rd Circ. Rejects Janssen, Bristol Myers Pricing AppealA split Third Circuit panel Thursday shot down another challenge to the Medicare drug pricing negotiation, this time rejecting a consolidated appeal from Bristol Myers Squibb and Janssen and upholding a lower court's finding that the program is indeed voluntary and therefore constitutional. 
- 
									September 04, 2025
									Doc Tells 1st Circ. Acquitted Conduct Marred Drug SentenceA Massachusetts psychiatrist convicted over an alleged scheme to import and dispense nonapproved forms of addiction medication on Thursday told the First Circuit the trial judge wrongly ran afoul of limitations on the consideration of acquitted conduct in federal sentencings when handing him a three-year prison term. 
- 
									September 04, 2025
									4th Circ. Affirms Gardasil's Vaccine Table InclusionA unanimous Fourth Circuit panel affirmed Thursday that adding the human papillomavirus vaccine Gardasil to the Vaccine Act's injury table did not violate the U.S. Constitution, rejecting three plaintiffs' arguments that the Secretary of Health and Human Services lacks the authority to make additions to the table without an act of Congress. 
- 
									September 04, 2025
									Generic Drug Org Backs MSN In High Court Entresto AppealThe Association for Accessible Medicines has thrown its weight behind MSN Pharmaceuticals in the company's U.S. Supreme Court challenge to a Federal Circuit decision blocking its generic version of Novartis' blockbuster cardiovascular drug Entresto, saying Wednesday that the appeals court took the wrong approach to patent validity. 
- 
									September 04, 2025
									GSK Adds Moderna's New COVID Vaccine To Del. IP SuitGlaxoSmithKline Biologicals is broadening its patent infringement suit against Moderna Inc. to include the latter's new family of COVID-19 vaccines, mNEXSPIKE. 
- 
									September 04, 2025
									Why The Harvard Funding Case Is 'Clear As Mud' On AppealA sweeping Harvard University victory in a suit challenging President Donald Trump's block on $2.2 billion in grant funding tees up a high-stakes appeal that experts say may turn on a wonky jurisdictional issue on which the U.S. Supreme Court seems to lack any sort of consensus. 
Expert Analysis
- 
								Series Brazilian Jiujitsu Makes Me A Better Lawyer  Competing in Brazilian jiujitsu – often against opponents who are much larger and younger than me – has allowed me to develop a handful of useful skills that foster the resilience and adaptability necessary for a successful legal career, says Tina Dorr of Barnes & Thornburg. 
- 
								
								Fed. Circ. In April: Introducing New Evidence During IPR  The Federal Circuit's decision in Sage Products v. Stewart last month upheld the Patent Trial and Appeal Board's decision to allow a petitioner to rely on case-dispositive evidence beyond prior art references, affording petitioners in inter partes review proceedings greater latitude in the timing of evidence presentation, say attorneys at Knobbe Martens. 
- 
								
								FDA Commissioner Speech Suggests New Vision For Agency.jpg)  In his first public remarks as U.S. Food and Drug Administration commissioner, Marty Makary outlined an ambitious framework for change centered around cultural restoration, scientific integrity, regulatory flexibility and selective modernization, and substantial enforcement shifts for the food and tobacco sectors, say attorneys at Arnall Golden. 
- 
								
								DOJ Export Declination Highlights Self-Reporting Benefits  The U.S. Department of Justice's recent decision not to prosecute a NASA contractor, despite a former employee pleading guilty to facilitating unlicensed exports, underscores the advantages available to companies that self-report sanctions violations, cooperate with investigations and implement timely remediation, say attorneys at Cleary. 
- 
								
								AG Watch: Texas Expands Use Of Consumer Protection Laws.jpg)  In recent years under Attorney General Ken Paxton, Texas has demonstrated the breadth of its public interest authority by bringing actions in areas not traditionally associated with consumer protection law, including recent actions involving sports and public safety, say attorneys at Kelley Drye. 
- 
								Series Power To The Paralegals: An Untapped Source For Biz Roles  Law firms looking to recruit legal business talent should consider turning to paralegals, who practice several key skills every day that prepare them to thrive in marketing and client development roles, says Vanessa Torres at Lowenstein Sandler. 
- 
								
								A Path Forward For Colo. Pot Products After Failed Safety Test.jpg)  As cannabis products in Colorado face increasingly rigorous contamination testing, decontamination and remediation can be an alternative to destruction after a failed safety check, in certain circumstances, so understanding the nuances of these procedures is vital, say attorneys at Troutman Pepper. 
- 
								Series Playing Poker Makes Me A Better Lawyer  Poker is a master class in psychology, risk management and strategic thinking, and I’m a better attorney because it has taught me to read my opponents, adapt when I’m dealt the unexpected and stay patient until I'm ready to reveal my hand, says Casey Kingsley at McCreadyLaw. 
- 
								
								What EU 'Killer Acquisition' Study Means For Pharma Deals  The European Commission’s recent study of pharmaceutical companies' acquisitions of emerging competitive threats, the first of its kind globally, has important implications for the industry, and may lead to increased awareness of merger control risks in collaborative agreements, say lawyers at Paul Weiss. 
- 
								
								Legal Risks For Providers Discussing Psychedelic Therapies  The emergence of psychedelic therapies as potential treatments for mental health conditions and other ailments continues to garner significant attention, but the legal landscape surrounding discussions and referrals remains fraught with complexity, creating potential risks for healthcare providers and institutions, says Kimberly Chew at Husch Blackwell. 
- 
								Series Law School's Missed Lessons: Becoming A Firmwide MVP  Though lawyers don't have a neat metric like baseball players for measuring the value they contribute to their organizations, the sooner new attorneys learn skills frequently skipped in law school — like networking, marketing, client development and case evaluation — the more valuable, and less replaceable, they will be, says Alex Barnett at DiCello Levitt. 
- 
								
								Trade Secrets Would Likely See Court Protection From GenAI  The advent of generative artificial intelligence has given rise to debate about how this technology will affect intellectual property rights and trade secret protections in particular, but courts to date have protected owners when technological advances have facilitated new means for trade secret theft, say attorneys at Kilpatrick Townsend. 
- 
								
								A Breakdown Of Trump's Order On Drug Pricing  The Trump administration may attempt to effectuate through rulemaking a recently issued executive order on lowering drug prices, which would likely have an adverse effect on stakeholders and trigger litigation, say attorneys at Debevoise. 
- 
								
								Cosmetic Co. Considerations As More States Target PFAS  In the first quarter of the year, seven states introduced or passed legislation focused on banning the sale of cosmetics that contain PFAS, making it necessary for businesses to adjust their product testing and supply chain practices, product formulations, marketing strategies, and more, say attorneys at Alston & Bird. 
- 
								
								Del. Bill Reflects Nat'l Tug-Of-War Between Cannabis, Alcohol  As Delaware's bill targeting hemp-derived THC beverages and ingestible products moves through the general assembly, it reads like a local regulatory fix — but in reality, it's a microcosm of a national power struggle playing out state-by-state across the cannabis frontier, says attorney Peter Murphy. 
